Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

AIMS: Treatment with sodium–glucose co‐transporter 2 (SGLT2) inhibitors improves outcomes in patients with chronic heart failure (HF) with reduced ejection fraction. There is limited experience with the in‐hospital initiation of SGLT2 inhibitors in patients with acute HF (AHF) with or without diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Tromp, Jasper, Ponikowski, Piotr, Salsali, Afshin, Angermann, Christiane E., Biegus, Jan, Blatchford, Jon, Collins, Sean P., Ferreira, João Pedro, Grauer, Claudia, Kosiborod, Mikhail, Nassif, Michael E., Psotka, Mitchell A., Brueckmann, Martina, Teerlink, John R., Voors, Adriaan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Study Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358952/
https://www.ncbi.nlm.nih.gov/pubmed/33609072
http://dx.doi.org/10.1002/ejhf.2137

Ejemplares similares

Ejemplares similares